Table 1.

IL-23 maintains malignant potential of tumors in equilibrium

α-AGP3/α-IFNγα-IL23p19/α-IFNγ
Outgrowth165*
Tumor free1832
α-AGP3/cIgα-IL23p19/cIg
Outgrowth00
Tumor free3436
α-AGP3/α-CD4/-CD8/-IFNγα-IL23p19/α-CD4/-CD8/-IFNγ
Outgrowth2211**
Tumor free2034
α-AGP3/cIgα-IL23p19/cIg
Outgrowth23
Tumor free4139
α-AGP3/α-IFNγα-IL10R/α-IFNγα-IL23p19/-IL-10R/α-IFNγ
Outgrowth810***0****
Tumor free82618
α-AGP3/cIgα-IL10R/cIgα-IL23p19/-IL-10R/cIg
Outgrowth100
Tumor free153518

NOTE: Composite of data from Figs.2, 5, and Supplementary Fig. S4, showing the number of mice with tumor outgrowth versus those remaining tumor free following intervention with cIg, anti-IFN-γ, or anti-CD4/CD8/IFN-γ cocktail (stage III). Statistical analysis was carried out by Fishers Exact test, compared against equivalent α-AGP3 group, *, P = 0.0036, **, P = 0.0087, ***, P = 0.2056, ****, P = 0.0007.